Ethyl-EPA in Alzheimer's disease - a pilot study

被引：72

作者：

Boston, PF

Bennett, A

Horrobin, DF

Bennett, CN

机构：

[1] Nether Edge Hosp, Michael Carlisle Ctr, Sheffield S11 9BF, S Yorkshire, England

[2] Laxdale Ltd, Stirling FK7 9JQ, Scotland

来源：

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 2004年 / 71卷 / 05期

关键词：

D O I：

10.1016/j.plefa.2004.07.001

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

This pilot study of ethyl-eicosapentaenoate (ethyl-EPA) in the treatment of Alzheimer's disease aimed to estimate the magnitude of any change in measures of cognition during a 12-week treatment period. A simple linear design was used in which each patient had a baseline period of 12 weeks without treatment, followed by 12 weeks' treatment with ethyl-EPA. Blood samples were taken both before and after the treatment period to measure erythrocyte membrane fatty acids. Assessments comprised cognitive measures and visual analogue ratings of overall assessment of functioning. There was little difference between treatment and baseline periods in the rate of decline of efficacy measures, except for a small improvement in carer's visual analogue rating (P = 0.02). It was concluded that it is unlikely there were any clinically important treatment effects of ethyl-EPA on cognition during the 12-week treatment period. A longer treatment period may be necessary to demonstrate efficacy of ethyl-EPA in this disorder. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：341 / 346

页数：6

共 16 条

[1]

CORRIGAN FM, 1991, ANN NY ACAD SCI, V640, P250

[2] Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content [J].